| abstract |
The presently described invention relates to a biodegradable and biocompatible delivery system of a substantially pure crystalline form of a sustained-release microparticulate composition of the fluidity of a bioactive agent such as, for example, nimodipine, a therapeutic form of the substantially pure crystalline form of the bioactive agent And a method for treating the blockage of the great cerebral artery in a subarachnoid space with the risk of blockage caused by brain injury in a mammal, comprising the steps of: reducing the sign or symptom of at least one delayed complication associated with brain injury . |